ALKS-5461

Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461
Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461
Endpoints
Alkermes
FDA
ALKS-5461
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Xconomy
Alkermes
FDA
advisory panels
ALKS-5461
major depressive disorder
Flag link:
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
CP Wire
Alkermes
ALKS-5461
major depressive disorder
FDA
Flag link:
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
Alkermes
ALKS-5461
Flag link:
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
Flag link:
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
TheStreet.com
FDA
drug approvals
Alkermes
ALKS-5461
CytRx
aldoxorubicin
Dynavax Technologies
HEPLISAV-B
Intra-Cellular Therapies
ITI-007
Novan
SB204
Portola Pharmaceuticals
betrixaban
PTC Therapeutics
ataluren
Rigel Pharmaceuticals
fostamatinib
TG Therapeutics
ublituximab
Flag link:
Alkermes slammed as top depression drug fails two PhIIIs
Alkermes slammed as top depression drug fails two PhIIIs
Fierce Biotech
Alkermes
ALKS-5461
clinical depression
clinical trials
Flag link: